Just In
- 3 hrs ago Russian Influencer Starves His Newborn To Death With Sunlight Diet, Know Dos And Don’ts Of This Diet
- 5 hrs ago Mahavir Jayanti 2024: Date, Time, History, Celebrations And Teachings Of Lord Mahavir In Jainism
- 6 hrs ago Parineeti Chopra Saree Looks: Check Amar Singh Chamkila Actor's Regal Fashion Statements
- 8 hrs ago Vidya Balan's 'Do Aur Do Pyaar' Urban Boho Style Avatar Is Relatable And Inspiring, Check Her Modern Avatar!
Don't Miss
- Sports IPL 2024: Gautam Gambhir Always Knew Sunil Narine Would Become A T20 Legend
- Movies Aavesham OTT Rights: Fahadh Faasil's Latest Action Comedy By Jithu Madhavan Closes A Crazy Deal
- News Neha Was Friends With Accused Fayaz, Not Lovers, Says Victim's Father
- Education UP Board 12th Result Toppers List 2024; Check the Names, Ranks, Marks and Districts here
- Finance Elon Musk Postpones India Trip, Tesla's Indian Market Entry Delayed
- Technology Best Noise-Cancelling Earbuds Under Rs 5,000: CMF Buds Pro, Redmi Buds 5, Realme Buds Air 5, and More
- Automobiles Tesla CEO Elon Musk's Much-Awaited Visit to India Deferred, Leaving Questions Unanswered
- Travel Journey From Delhi To Ooty: Top Transport Options And Attractions
AIIMS Delhi To Start Booster Dose Trial Of Intranasal Covid Vaccine From March 11
The AIIMS will start the booster dose trial of Bharat Biotech's intranasal COVID-19 vaccine from Friday. The booster dose will be given to those who have received both the doses of either Covaxin or Covishield at least five months ago but not more than seven months back, Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS, New Delhi told PTI.
India is yet to approve the use of intranasal vaccine against COVID-19, BBV154 developed by the Hyderabad based company.
The Drugs Controller General of India (DCGI) in January had given permission to Bharat Biotech to conduct a phase-3 randomized, multi-centric study to evaluate the immunogenicity and safety of the booster dose in participants previously vaccinated with Covishield or Covaxin.
"We got the ethical approval for initiating the booster dose trial on Wednesday. Registration for the participants will start from March 10 via email --HYPERLINK "mailto:[email protected]"[email protected] --- and WhatsApp (7428847499) for those who received both the doses of either Covaxin or Covishield more than 5 months but less than 7 months ago," Dr Rai said.
AIIMS, New Delhi is one of the five sites where the booster trial for the nasal vaccine will be conducted.
BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.
- healthCOVID Surge In India: Do You Need A COVID-19 Booster Shot?
- disorders cureCommon COVID Symptoms In Fully Vaccinated Individuals: What You Should Know
- wellnessMild COVID Linked To Life-Threatening Blood Clots, Increased Risk Of Cardiovascular Disease; Study
- wellnessCOVID-19 Variants In India: New COVID Variant May Pose Threat To Elderly People
- basicsCovid-19 Linked To Early Onset Of Periods: What You Need To Know
- wellnessCOVID XBB Variants Of Omicron In India: What You Should Know
- disorders cureNew Omicron Subvariant BQ.1 Detected In Maharashtra: What You Should Know
- disorders cureWhat Is ‘Centaurus,’ New Fast-Spreading Covid Variant: Everything You Need To Know
- health75 Years Of Independence, 75 Days Of Free COVID Booster Shots; For Everyone Aged 18-59 From 15 July
- wellnessWhat Are The Health Risks Of Getting COVID The Second Or Third Time? 7 Important Points
- wellnessHow Does COVID Spread During Short Conversations?
- wellnessNTAGI To Review Covaxin Corbevax Data For 6-12 Years Thursday, Discuss Reducing Booster Dose Gap